Vaccine Production — Serum & Single-Use Bag Selection for Vero, MDCK & BHK-21

Viral vaccine manufacturing relies on continuous cell lines as the primary production platform — Vero for rabies, polio and dengue; MDCK for influenza; BHK-21 for foot-and-mouth disease and veterinary vaccines. Each cell line has specific serum requirements that directly impact virus propagation yield and regulatory compliance. Post-COVID, serum supply chain reliability has become a critical raw material risk.

Kontakt Im Shop ansehen

Cost optimisation in vaccine production: Newborn Calf Serum (NCS) and Calf Serum (CS) are the preferred cost-effective alternatives to FBS for Vero, MDCK and BHK-21 cell maintenance and virus propagation — equivalent growth support at 30–60% lower cost.

Cell Line — Serum Selection Guide

Cell Line	Vaccine Application	Recommended Serum	Concentration
Vero	Rabies (inactivated), Polio (IPV/OPV), Dengue, Japanese Encephalitis, Yellow Fever, SARS-CoV-2	NCS ≤10 days — AU or US origin	5–10% for maintenance; 2–5% during virus propagation
MDCK	Influenza (seasonal and pandemic), respiratory virus research	NCS ≤10 days — AU or US origin	5–10% for cell maintenance; serum-free for virus infection step (trypsin-dependent influenza)
BHK-21	Foot-and-mouth disease (FMD), rabies, veterinary virus vaccines	CS — AU or US origin	5–10% for routine culture; 2–5% during production phase
HEK293	Adenoviral vectors for vaccine delivery, recombinant subunit antigens	FBS Low Endotoxin ≤5 EU/mL	10% for maintenance; reduce to 2% or serum-free at production
MRC-5 / WI-38 (diploid)	Varicella, hepatitis A, rabies (human diploid cell vaccine)	FBS Low Endotoxin ≤5 EU/mL	10% — diploid cells require FBS quality; NCS/CS not recommended for primary diploid strains

NCS vs Calf Serum vs FBS — Cost Optimisation

Serum	Donor Age	Cost vs FBS	Best For	Not Suitable For
NCS ≤10 days	≤10 days	~30–50% lower	Vero, MDCK, BHK-21 routine maintenance and virus propagation	Diploid cell strains (MRC-5, WI-38), sensitive primary cultures
Calf Serum (CS)	14 days – 6 months	~40–60% lower	BHK-21 large-scale FMD/veterinary vaccine production. High-volume cell banking.	Diploid cells, applications requiring low IgG
FBS, endotoxinarme	Fetal	Reference	Diploid cell strains, HEK293 adenoviral vectors, CHO recombinant antigens, sensitive primary cultures	Cost-sensitive bulk Vero/MDCK/BHK-21 production where NCS/CS perform equivalently

Origin Selection — BSE/TSE Documentation for Vaccine Submissions

Herkunft	BSE/TSE Status	Documentation	Best For
Australian	OIE Negligible Risk — no indigenous BSE	EDQM CEP available, USDA import permitted	EU and US regulatory submissions requiring maximum TSE/BSE documentation. WHO-prequalified vaccine programmes.
US Origin	USDA 9CFR licensed	9CFR CoA, FDA-aligned	US regulatory submissions. Cost-effective option for USDA-documented programmes.
EU Origin	EU TSE/BSE surveillance — controlled risk	EDQM CEP available	EU regulatory submissions. DACH market documentation requirements.

Vaccine Production Phases — Complete Product Map

Phase	Step	Recommended Product
Cell Bank	MCB and WCB preparation for Vero, MDCK, BHK-21	NCS AU origin — highest BSE documentation for cell bank regulatory filing
Seed Train	Cell expansion from WCB to production density	NCS or CS at 5–10%. Rocker Bags for suspension seed stages.
Infection	Virus inoculation and propagation	Reduce to 2–5% or switch to serum-free at infection step — reduces serum interference with virus quantification assays
Harvest	Virus harvest, clarification, primary purification	2D Single-Use Bags for closed virus pool collection and storage
Formulation	Virus concentration, formulation, filling	BSA, endotoxinarme in stabilisation buffer if required

Single-Use Bags for Vaccine Manufacturing

Product	Volume	Vaccine Application	Key Specification
Rocker Bag	0.5–200 L	Vero or MDCK cell expansion in rocking wave bioreactor for virus seed preparation. BHK-21 FMD scale-up.	USP Class VI. Gamma sterilised ≥25 kGy ISO 11137. Corning and HyPerforma compatible. ISO 13485.
2D Single-Use Bags	150 mL–50 L	Virus harvest collection, media preparation, buffer storage, intermediate virus pools	USP Class VI. Gamma sterilised. Drop-in Sartorius Flexboy®. GMP documentation. ISO 13485.
3D Single-Use Bags	50–1,000 L	Large-volume media preparation for clinical-scale vaccine manufacturing	MPX tubing. GMP documentation package. Gamma sterilised. ISO 13485.

Frequently Asked Questions

Can NCS replace FBS for Vero cell vaccine production?

Yes — for routine Vero cell maintenance and virus propagation (rabies, polio, dengue), NCS performs equivalently to FBS at 30–50% lower cost. NCS from calves ≤10 days provides a rich growth factor composition that supports Vero cell health and virus yield. Australian origin NCS provides the strongest regulatory documentation for WHO-prequalified vaccine programmes.

Why is serum reduced or removed at the virus infection step?

High serum concentrations at the virus infection step can interfere with virus adsorption to cell surface receptors — reducing infection efficiency. Additionally, serum proteins interfere with plaque assay and TCID50 quantification of virus yield. Reducing serum to 2% or switching to serum-free medium during virus propagation is standard practice for Vero and MDCK-based vaccine production.

Which origin NCS for WHO-prequalified vaccine submissions?

Australian origin NCS is the preferred choice — OIE negligible BSE/TSE risk, EDQM CEP available, USDA import permitted. Australian origin provides the strongest regulatory documentation for both EU (EMA) and US (FDA) submissions and WHO prequalification dossiers.

What single-use bag for virus harvest collection?

2D Single-Use Bags in 2–10 L format are standard for virus harvest collection from Vero or MDCK roller bottle or bioreactor runs. Closed system collection directly into gamma-sterilised bags minimises contamination risk and reduces handling steps. 3D bags in 50–200 L are used for pooled harvest intermediates in large-scale manufacturing.

← All Application Guides Overview

Request Free Test Volumes & Origin Documentation

NCS and CS samples with Australian/US BSE documentation. Lot-specific CoA and CoO. Batch reservation for vaccine manufacturing campaigns.
Email: info@seamlessbio.de | +49 851 37932226